Published in Genes Dev on April 01, 2008
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 10.71
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res (2008) 8.97
Biomarkers for epithelial-mesenchymal transitions. J Clin Invest (2009) 8.76
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 8.33
TGF-beta-induced epithelial to mesenchymal transition. Cell Res (2009) 7.88
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13
miRNAs in human cancer. J Pathol (2010) 6.02
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer (2009) 5.47
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12
ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell (2009) 5.03
MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol (2008) 4.45
The consensus molecular subtypes of colorectal cancer. Nat Med (2015) 4.35
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature (2015) 4.18
The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep (2010) 4.05
The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 3.68
Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev (2013) 3.63
To differentiate or not--routes towards metastasis. Nat Rev Cancer (2012) 3.59
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev (2009) 3.58
Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell (2010) 3.53
MicroRNAs in cancer. Annu Rev Pathol (2013) 3.50
Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One (2010) 3.50
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 3.46
Non-coding RNAs as regulators of embryogenesis. Nat Rev Genet (2011) 3.36
MicroRNAs in human cancer. Adv Exp Med Biol (2013) 3.19
Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J (2009) 3.11
miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep (2009) 3.03
Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.02
Experimental strategies for microRNA target identification. Nucleic Acids Res (2011) 3.00
p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med (2011) 2.93
MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res (2009) 2.93
MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell (2013) 2.92
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest (2011) 2.90
Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol (2009) 2.89
MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res (2010) 2.83
MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer (2012) 2.78
Cancer stem cells: the challenges ahead. Nat Cell Biol (2013) 2.78
miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells (2009) 2.64
The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol (2009) 2.56
Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One (2010) 2.55
MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems. Genes Dev (2010) 2.51
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther (2009) 2.50
Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol (2010) 2.49
An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell (2011) 2.49
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev (2011) 2.48
Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol (2012) 2.46
Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol (2010) 2.45
Adherens junction: molecular architecture and regulation. Cold Spring Harb Perspect Biol (2009) 2.45
Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene (2011) 2.42
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut (2012) 2.40
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res (2010) 2.39
MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal (2009) 2.38
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res (2011) 2.32
The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31
A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int (2011) 2.30
Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res (2011) 2.29
The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J (2011) 2.29
Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett (2011) 2.24
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res (2010) 2.13
Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell (2010) 2.12
The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol (2009) 2.06
Tissue organization by cadherin adhesion molecules: dynamic molecular and cellular mechanisms of morphogenetic regulation. Physiol Rev (2011) 2.06
miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem (2010) 2.05
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol (2013) 2.04
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat (2010) 1.98
Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res (2011) 1.96
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun (2014) 1.95
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med (2011) 1.94
Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem (2011) 1.94
New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) (2008) 1.94
Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol (2008) 1.91
Tumour angiogenesis regulation by the miR-200 family. Nat Commun (2013) 1.90
Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol (2009) 1.90
Roles of small RNAs in tumor formation. Trends Mol Med (2010) 1.89
Adult-specific functions of animal microRNAs. Nat Rev Genet (2013) 1.89
The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther (2010) 1.89
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer (2009) 1.85
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
MicroRNA regulation of cancer stem cells. Cancer Res (2011) 1.84
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol (2009) 1.84
MicroRNA-204/211 alters epithelial physiology. FASEB J (2010) 1.83
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 18.69
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 11.01
The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell (2001) 10.02
The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res (2007) 9.32
An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) (1995) 9.18
mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene (2007) 7.02
Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res (2007) 6.57
DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene (2005) 5.74
The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene (2007) 4.90
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest (2007) 4.80
Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays (2001) 4.73
Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res (2007) 4.65
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull (2006) 4.42
Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci U S A (2001) 4.20
NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene (2006) 3.91
Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol (2002) 3.82
Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol (2004) 3.64
Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle (2007) 3.62
Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A (2007) 3.59
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev (2006) 3.14
Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell (2007) 2.92
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
miR-200b mediates post-transcriptional repression of ZFHX1B. RNA (2007) 2.67
Identification of let-7-regulated oncofetal genes. Cancer Res (2008) 2.56
The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res (2006) 2.38
Reciprocal expression of lin-41 and the microRNAs let-7 and mir-125 during mouse embryogenesis. Dev Dyn (2005) 2.14
CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J (2004) 2.12
Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene (2006) 2.09
E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. Hum Mol Genet (2005) 1.95
The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. Int J Cancer (2006) 1.91
Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene (2006) 1.89
Differential expression and function of members of the zfh-1 family of zinc finger/homeodomain repressors. Proc Natl Acad Sci U S A (2000) 1.73
Expression of SIP1 in oral squamous cell carcinomas: implications for E-cadherin expression and tumor progression. Int J Oncol (2005) 1.64
Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch (2006) 1.49
Potential mRNA degradation targets of hsa-miR-200c, identified using informatics and qRT-PCR. Cell Cycle (2006) 1.45
The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res (2003) 1.42
CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia. Apoptosis (2008) 1.17
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer (2010) 3.95
Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle (2007) 3.62
Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A (2007) 3.59
c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J (2002) 2.91
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
Identification of let-7-regulated oncofetal genes. Cancer Res (2008) 2.56
Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer (2011) 2.49
CD95 promotes tumour growth. Nature (2010) 2.42
Molecular ordering of the initial signaling events of CD95. Mol Cell Biol (2002) 2.36
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res (2008) 2.35
The CD95 type I/type II model. Semin Immunol (2003) 2.34
Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer (2007) 2.31
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J (2004) 2.12
Interdimer processing mechanism of procaspase-8 activation. EMBO J (2003) 2.03
Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.89
Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta (2013) 1.85
MicroRNA-204/211 alters epithelial physiology. FASEB J (2010) 1.83
The role of receptor internalization in CD95 signaling. EMBO J (2006) 1.80
miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell (2010) 1.76
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila) (2009) 1.75
MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov (2012) 1.75
Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene (2004) 1.66
Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein. J Biol Chem (2001) 1.51
Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell (2005) 1.45
Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity (2006) 1.43
Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci U S A (2003) 1.41
Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol (2005) 1.37
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol (2009) 1.37
Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol (2008) 1.37
Apoptosis-independent functions of killer caspases. Curr Opin Cell Biol (2002) 1.32
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia (2010) 1.31
Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J (2006) 1.29
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol (2012) 1.29
MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle (2009) 1.28
Programmed cell death: Apoptosis meets necrosis. Nature (2011) 1.28
Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer (2011) 1.27
CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia. Apoptosis (2008) 1.17
CD95 is cytoprotective for intestinal epithelial cells in colitis. Inflamm Bowel Dis (2010) 1.17
Cell death in the colonic epithelium during inflammatory bowel diseases: CD95/Fas and beyond. Inflamm Bowel Dis (2010) 1.16
Regulation of apoptosis by ubiquitination. Immunol Rev (2003) 1.13
Exploring complex miRNA-mRNA interactions with Bayesian networks by splitting-averaging strategy. BMC Bioinformatics (2009) 1.13
The death effector domain protein family. Oncogene (2003) 1.11
Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest (2014) 1.10
Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res (2009) 1.10
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest (2012) 1.07
A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol (2009) 1.06
Gadd45 beta mediates the protective effects of CD40 costimulation against Fas-induced apoptosis. Blood (2003) 1.05
miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression. Am J Pathol (2013) 1.04
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res (2010) 1.04
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol (2011) 1.01
Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness. J Biol Chem (2004) 1.01
Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep (2004) 1.00
Local gene density predicts the spatial position of genetic loci in the interphase nucleus. Exp Cell Res (2005) 1.00
NF-kappaB protects from the lysosomal pathway of cell death. EMBO J (2003) 1.00
The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov (2011) 0.99
A role for caspase-8 and c-FLIPL in proliferation and cell-cycle progression of primary hepatocytes. Carcinogenesis (2005) 0.99
Cell cycle effects by C-FADD depend on its C-terminal phosphorylation site. J Biol Chem (2003) 0.98
Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res (2011) 0.96
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem (2007) 0.95
Actin dependent CD95 internalization is specific for Type I cells. FEBS Lett (2003) 0.94
Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. Endocrinology (2009) 0.94
Assays of endogenous caspase activities: a comparison of mass spectrometry and fluorescence formats. Anal Chem (2006) 0.93
DEDD regulates degradation of intermediate filaments during apoptosis. J Cell Biol (2002) 0.93
Intermediate filaments control the intracellular distribution of caspases during apoptosis. Am J Pathol (2004) 0.92
The TNF receptor 1: a split personality complex. Cell (2003) 0.91
PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15. Mol Cell Biol (2008) 0.90
The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril (2009) 0.89
Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Mol Cancer Res (2007) 0.89
The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. Mol Cell Endocrinol (2009) 0.88
microRNAs and death receptors. Cytokine Growth Factor Rev (2008) 0.88
How apoptosis got the immune system in shape. Eur J Immunol (2007) 0.88
Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther (2013) 0.86
CD95 is part of a let-7/p53/miR-34 regulatory network. PLoS One (2012) 0.85
Role of beta(3)-endonexin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor. J Cell Sci (2002) 0.85
The relevance of NF-kappaB for CD95 signaling in tumor cells. Cell Cycle (2004) 0.84
miRConnect: identifying effector genes of miRNAs and miRNA families in cancer cells. PLoS One (2011) 0.82
Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. Hum Mol Genet (2009) 0.82
The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol (2011) 0.82
Fas ligand-Fas signaling participates in light-induced apoptotic death in photoreceptor cells. Invest Ophthalmol Vis Sci (2012) 0.81
miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers. BMC Genomics (2013) 0.81
Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol (2012) 0.80
Two faces of caspase-8. Nat Immunol (2002) 0.80
Synthesis of a high-purity chemical library reveals a potent inducer of oxidative stress. Chembiochem (2010) 0.79
Serine protease inhibitor 6-deficient mice have increased neutrophil immunity to Pseudomonas aeruginosa. J Immunol (2007) 0.77
An interview with Dr. Marcus E. Peter on his highly cited paper published in Cell Cycle. Cell Cycle (2009) 0.76
Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp (2015) 0.75
Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 0.75
Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome. Gene (2004) 0.75
Methods to analyze the palmitoylated CD95 high molecular weight death-inducing signaling complex. Methods Enzymol (2008) 0.75